Discontinuation of Hormonal Contraception: A Systematic Review and Metanalysis

By Joni K Roberts, DrPH, CHES; Katherine C. McNabb, MSN, RN; Alanna Bergman, MSN, AGNP-BC; Tanjila Taskin PhD, MPH, CPH; Bella Mualem, BS, and Oluwabunmi Ogungbe, PhD, MPH, RN

Facebook
Twitter
LinkedIn

Citation

Roberts J, McNabb K, Bergman A, Taskin T, Mualem B, Ogungbe O. Discontinuation of hormonal contraception: A systemic review and metanalysis. HPHR. 2023;76. https://doi.org/10.54111/0001/XXX2

The Role of Direct-to-Consumer Sexually Transmitted Infection Screening for Survivors of Sexual Assault

Abstract

Introduction

Around the globe, unintended pregnancy rates remain high, especially among women in low and middle-income countries. A major contributor is contraceptive discontinuation. This study aims to synthesize the rates of early hormonal contraceptive discontinuation (i.e., discontinuation prior to 12 months of use) and the impact of side effects on discontinuation.

Methods

A systematic review of seven databases covered articles published between 2011 and 2021. Observational studies that assessed choices about hormonal contraceptive use were included in the final review. As reported in each article reviewed, the pooled proportions of early contraceptive discontinuation rates were calculated using a random effects model. Qualitative and quantitative data about the influence of side effects on discontinuation of hormonal contraception were synthesized using a narrative approach.

Results

Fifty studies met the inclusion criteria. The pooled overall early discontinuation rate was 26% (95% CI: 21–32%). The pooled early discontinuation rates for short-acting hormonal methods like oral contraceptives and injectables were 42% (95% CI: 20–67%) and 21% (95% CI: 7–40%), respectively. Meanwhile, the pooled discontinuation rates for long-acting hormonal methods like implants and intrauterine devices were 22% (95% CI: 16–28%) and 17% (95% CI: 11–24%), respectively. The side effects mentioned most frequently as contributing to hormonal contraceptive discontinuation were abnormal bleeding, abdominal pain, nausea, vomiting, cramping, headaches, mood changes, and sexual and genitourinary side effects.

Discussion/ Conclusion

High rates of early contraceptive discontinuation persist with varying levels of discontinuation based on contraceptive type. Side effects play a major role in hormonal contraceptive discontinuation. However, there is a dearth of evidence on managing side effects, making this an important area for future research.

Introduction

Despite the increasing usage of contraceptives among women of reproductive age worldwide, the rate of unintended pregnancies remains high. Between 2015 and 2019, 121 million unintended pregnancies occurred annually, with women in poorer countries accounting for most.1 According to a World Health Organization (WHO) study from 25 countries, method-related concerns, including side effects, are the most common reasons for contraceptive discontinuation.2-4 In fact, about one-third of unintended pregnancies in low and middle-income countries (LMICs) are attributed to contraceptive discontinuation.5

 

Researchers have identified many reasons for hormonal contraceptive discontinuation based on side effects, including irregular bleeding, amenorrhea, weight gain, pain, and changes to sexual experience.6 There are variations in contraceptive discontinuation by country and method, with shorter-acting methods of birth control (such as oral contraceptive pills and injectables) having higher reported rates of early discontinuation compared to long-acting methods.5,7,8

 

As the use of long-acting reversible contraceptives (LARCs) has gained ground within the past decade,9 it is vital to synthesize existing evidence on specific side effects concerning early discontinuation rates to address the issue of unintended pregnancies. This integrative review of quantitative and qualitative studies is a first step in identifying a baseline framework for analyzing early hormonal contraception discontinuation rates in light of the prevalence of specific side effects.

 

Methods

Search Strategy

A systematic literature search was performed in seven databases between January 2011 and August 2021 using keywords and MeSH terms. This search was restricted to the past decade to account for changes in LARC uptake among women after the contraceptive CHOICE project.9 Comprehensive search strategies are in the electronic supplementary material (Appendix A).

Eligibility criteria and study selection

Eligible papers from the seven different electronic database searches were first identified based on the titles of articles that discussed contraceptives, side effects, and/or discontinuation. This yielded 2160 results, of which 853 were duplicates, providing 1307 unique articles. At least two independent reviewers then screened the title and abstract. Studies were eligible if they were peer-reviewed, written in English, and focused on non-randomized observational studies that assessed the choice of hormonal contraceptive use in navigating the competing concerns of side effects and protection. This resulted in another 1165 articles being excluded.

 

Two reviewers completed an independent full-text review of the remaining 142 articles. During the full-text review, an additional 92 studies were excluded for reasons ranging from being outside the specified time frame to lack of a full-text manuscript or availability in English. Discrepancies between reviewers were resolved through discussions or the help of an independent third reviewer. Ultimately, 50 full texts were included for review. Figure 1 shows the PRISMA consort diagram.

Figure 1. PRISMA consort diagram.

Figure 1. PRISMA consort diagram.

Data Analysis

For each eligible article, data extracted included the author and publication year, country, study setting, sample size, disease, population, setting, age of participants, type of contraception, and outcomes reported. Using the “metaprop” package in Stata/IC 16.1, we pooled the proportions of contraceptive discontinuation rates reported in each article using a random effects model.10 We conducted a subgroup analysis by hormonal contraceptive method to generate the pooled estimates. The calculated pooled estimates and exact 95% confidence intervals are displayed in forest plots in Figure 2. Due to the lack of adequate primary quantitative data, data on contraceptive side effects was synthesized using a narrative approach.

Figure 2. Early Discontinuation Rates by Contraceptive Type

Figure 2. Early Discontinuation Rates by Contraceptive Type

Results

Characteristics of Studies

The final sample comprised 50 studies. Thirty-seven utilized quantitative research designs, 11 studies employed qualitative designs, and two studies adopted mixed- or multi-method research designs. The quantitative studies encompassed 50,855 women and spanned 22 cohort studies, 14 cross-sectional studies, and one case-control study. Sample sizes in these quantitative studies ranged from 116 to 9,256. Data was collected through questionnaires, structured interviews, and chart reviews. The qualitative studies offered the perspectives of 362 women and gathered data through 286 in-depth interviews and 19 focus groups. Finally, the mixed methods studies collected quantitative data from 281 surveys and qualitative data from 48 in-depth interviews. Most of the data in the included studies were collected between 2006 and 2019. Table 1 summarizes the characteristics of the included studies, while Appendix D details the aims and themes of the qualitative studies included.

Table 1: Characteristics of Included Studies

First Author & Year

Country 

Study Design 

Birth Control Methods

Mean Age

(SD)

Sample Size 

Length of Follow-up (Months)

Parous2

Oral

Implant

Vaginal Ring

Patch

Injection

Hormonal IUD

Copper IUD

Other

Romano 2018

United States

Case-Control

 

      

17 (2)

394

Varied

Mixed

Akilimali 2020

DRC

Cohort

 

      

17.9 (6.3)

415

24

Mixed

Bachofner 2018

Switzerland

Cohort

     

33.4 (6.8)

755

60

Mixed

Bengtson 2013

Uganda & Zimbabwe

Cohort

   

   

NR

231

96

NR

Briggs 2016

Multi-Site

Cohort

       

NR

3258

12

NR

Burke 2021

United States

Cohort

 

NR

1700

24

Yes

Diedrich 2015

United States

Cohort

 

   

 

25.6 (6.0)

9256

6

Mixed

Ferreira 2014

Brazil

Cohort

35 (0.23)

1167

12

Mixed

Fruzzetti 2019

Italy

Cohort

       

NR

(Range:14 – 54)

354

48

Mixed

Grunloh 2013

United States

Cohort

 

   

 

NR

6167

6

Mixed

Jaisamrarn 2021

Thailand

Cohort

  

 

 

NR

1880

12

Mixed

Madden 2012

United States

Cohort

 

   

 

23.1 (5.6)

1178

36

Mixed

Maslyanskaya 2016

United States

Cohort

 

 

17.7 (1.8)

145

6

Mixed

Obijuru 2015

United States

Cohort

 

  

   

17 (1.8)

116

36

Mixed

Peterson 2019

United States

Cohort

 

      

23.7 (5.8)

544

12

Mixed

Roke 2016

New Zealand

Cohort

 

      

24.5

(Range:13 – 50)

252

12

NR

Saloranta 2020

Finland

Cohort

 

   

 

28.6

(IQR: 23.1 – 33.4)

2026

24

Mixed

Simmons 2019

United States

Cohort

 

NR

3688

24

Mixed

Sundell 2019

Sweden

Cohort

    

  

29

(Range:18 – 40)

1115

60

NR

Teunissen 2014

Netherlands

Cohort

 

      

26.9 (7.6)

214

36

Mixed

Vickery 2013

United States

Cohort

 

  

 

 

NR

427

12

Mixed

Weisberg 2014

Australia

Cohort

 

   

  

NR

311

36

Mixed

Wildemeersch 2017

Belgium

Cohort

     

 

35.1 (8.8)

356

120

Mixed

Adeyemi 2012

Nigeria

Cross-Sectional

    

   

34.04 (5.68)

433

n/a

Yes

Al-Jefout 2015

Jordan

Cross-Sectional

 

      

30.9 (4.9)

69

n/a

Yes

Beesham 2021

South Africa

Cross-Sectional

 

      

27

(IQR: 24 – 32)

120

n/a

NR

Fruzzetti 2016

Italy

Cross-Sectional

 

    

NR

(Range:14 – 42)

1809

n/a

Mixed

Gmedhin 2019

Ethiopia

Cross-Sectional

 

      

261

(Range:16 – 51)

229

n/a

Yes

Hirth 2021

United States

Cross-Sectional

NR

2632

n/a

Mixed

Hladky 2011

United States

Cross-Sectional

     

 

31.9 (0.3)

1,665

n/a

Mixed

Johnson 2013

Multi-Site

Cross-Sectional

35

2544

n/a

NR

Madden 2015

United States

Cross-Sectional

 

 

25.6 (5.9)

2590

n/a

Mixed

Mandle 2017

Multi-Site

Cross-Sectional

NR

1144

n/a

NR

Martin 2018

NR

Cross-Sectional

 

 

24.2 (4.4)

430

n/a

NR

Nageso 2018

Ethiopia

Cross-Sectional

 

      

24.5 (4.8)

683

n/a

Mixed

Roberts 2015

Nigeria

Cross-Sectional

 

      

33.6 (2.4)

128

n/a

Mixed

Tesfaye 2021

Ethiopia

Cross-Sectional

 

      

25.7 (5.1)

430

n/a

Yes

Dasari 2016

United States

Mixed Methods

 

  

21

15

n/a

Mixed

Schrumpf 2020

Ghana

Mixed Methods

  

  

29.4 (7.8)

135

n/a

Mixed

Alspaugh 2021

United States

Qualitative

        

45.1

(Range: 40 – 55)

20

n/a

NR

Austad 2020

Guatemala

Qualitative

  

 

29.8

(Range: 21 – 42)

24

n/a

Yes

Berndt 2021

United States

Qualitative

        

30

(Range: 16 – 44)

86

n/a

Mixed

Dolan 2021

Australia

Qualitative

    

  

NR

22

n/a

Mixed

Flore 2016

Australia

Qualitative

 

      

24.5

(Range: 18 – 39)

18

n /a

Mixed

Higgins 2015

United States

Qualitative

 

   

 

NR

52

n/a

NR

Hoggart 2013a

United Kingdom

Qualitative

 

      

NR

(Range: 16 – 22)

20

n/a

NR

Hoggart 2013b

United Kingdom

Qualitative

 

      

NR

(Range: 16 – 22)

20

n/a

NR

Kelly 2019

United States

Qualitative

 

    

17

(Range: 15 – 19)

21

n/a

NR

Sarfraz 2021

Pakistan

Qualitative

 

   

 

NR

(Range: 20 – 33)

27

n/a

Yes

Schmidt 2015

United States

Qualitative

     

 

18 (1.4)

43

n/a

Mixed

The largest proportion of studies was conducted in the WHO’s Region of the Americas (21). In contrast, the remaining studies were distributed across the Europe Region (9), the African Region (8), the Western Pacific Region (4), the Eastern Mediterranean Region (3), and the South-East Asian Region (1). Four studies were conducted at multiple sites.

 

The objectives of the studies were categorized into three main types: studies investigating the reasons for or factors associated with contraceptive choice and initiation; studies exploring the rates of, reasons for, and factors associated with contraceptive continuation or discontinuation; and studies aiming to more generally understand women’s perceptions of, attitudes about, and experiences with contraception.

 

Of the studies, 24 investigated LARCs, which included contraceptive implants (15), intrauterine devices (IUDs) (3), or both (6). An additional two studies focused on oral contraceptives, one on injectable contraception, and 21 on a combination of different forms of hormonal contraception. Two qualitative studies discussed contraceptive decision-making without specifying the forms of contraception.

 

The majority of studies targeted all women of reproductive age, with the lower age limit within the inclusion criteria (typically set at 18 years old) and the upper age limit between 44 and 50 years old. Twelve studies focused more specifically on adolescents or young adults, and one centered on midlife women.

Discontinuation Rates

Among the included studies that reported contraception discontinuation rates, high rates of early discontinuation were identified (as shown in Figure 2). The overall pooled discontinuation rate within 12 months or fewer of initiation was 26% (95% CI: 21–32%); however, discontinuation rates varied by contraceptive method. The hormonal contraceptive pill had the highest pooled discontinuation rate at 42% (95% CI: 20–67%). In contrast, the lowest discontinuation rate was observed for IUD use at 17% (95% CI: 11–24%). For implants and injectables, pooled discontinuation rates were 22% (95% CI: 16–28%) and 21% (95% CI: 7–40%) respectively. Studies reporting overall discontinuation for groups of women using multiple methods saw a pooled discontinuation rate of 38% (95% CI: 20–58%).

Contraceptive Discontinuation Related to Side Effects

Table 2. Contributions to the Synthesis of the Impact of Side Effects on Discontinuation

First Author & Year

Side Effect Categories

 Abnormal Bleeding

 Weight Gain

 Abdominal Pain & Cramping

 Headache

 Mood Changes

 Sexual & GU

Adeyemi 2012

   

Akilimali 2020

     

Al-Jefout 2015

Alspaugh 2021

    

Austad 2020

   

 

Bachofner 2018

  

Beesham 2021

     

Bengtson 2013

     

Berndt 2021

  

   

Briggs 2016

     

Burke 2021

 

  

Dasari 2016

  

Diedrich 2015

 

   

Dolan 2021

     

Ferreira 2014

     

Flore 2016

  

 

Fruzzetti 2016

 

Fruzzetti 2019

 

 

Gmedhin 2019

      

Grunloh 2013

 

   

Higgins 2015

    

Hirth 2021

      

Hladky 2011

 

  

Hoggart 2013a (Dickson)

 

 

Hoggart 2013b

 

Jaisamrarn 2021

 

  

Johnson 2013

 

  

 

Kelly 2019

   

Madden 2012

 

Madden 2015

 

Mandle 2017

  

Martin 2018

 

Maslyanskaya 2016

      

Nageso 2018

      

Obijuru 2015

    

Peterson 2019

     

Roberts 2015

 

  

Roke 2016

  

 

Romano 2018

 

    

Saloranta 2020

  

Sarfraz 2021

    

Schmidt 2015

 

 

 

 

 

Schrumpf 2020

 

 

 

Simmons 2019

 

 

Sundell 2019

 

 

 

 

 

Tesfaye 2021

 

 

 

Teunissen 2014

 

 

 

Vickery 2013

 

 

 

 

 

Weisberg 2014

 

 

Wildemeersch 2017

 

 

 

       

Women opted to discontinue hormonal contraception for a variety of reasons, the most common of which were abnormal bleeding, weight gain, abdominal pain and cramping, headache, mood changes, and sexual and genitourinary side effects. Table 2 indicates which studies discussed each of these side effect categories.

 

Abnormal Bleeding

Women reporting abnormal bleeding discontinued their hormonal contraceptive method more often than women experiencing any other type of side effect. Eighty-nine percent of the included studies cited abnormal bleeding as the primary for discontinuation. For instance, studies reported that between 9.6% and 81.9% of women who discontinued injectable contraceptives did so due to abnormal bleeding.11,12 Several studies found that increased bleeding or irregular bleeding was the most frequent reason for contraceptive method discontinuation among LARC users (from 14.1% to 65.40%).13-15 Other studies found that abnormal bleeding caused by other forms of hormonal contraception led to discontinuation rates of between 5.3% and 15.0%.16,17

 

The qualitative studies corroborated the quantitative data, offering firsthand accounts of how abnormal bleeding could lead to hormonal contraceptive discontinuation.18-24 A typical account came from a 28-year-old user of a hormonal contraceptive implant: “There wasn’t really any gap where I didn’t have the spotting and that’s the main reason I did get it taken out.20

 

Weight Gain

The second most commonly reported reason for hormonal contraceptive method discontinuation was weight gain, mentioned in 55.6% of the included studies. Quantitative studies indicated that between 1.4% and 40.9% of women who discontinued hormonal contraceptives did so due to weight gain.11,13,14

In qualitative studies, women frequently reported fear of weight gain as a barrier to initiating hormonal contraceptive methods. One woman using injectable contraceptives stated, “The shot made me gain a lot of weight. I gained 30 pounds 3 weeks after I had it”. 23

 

Abdominal Pain, Nausea, Vomiting, and Cramping

Abdominal pain, nausea, vomiting, and cramping were indicated as reasons for discontinuing hormonal contraceptive methods in 33% of the included studies. Several studies found that between 2% and 40.47% of women who used LARCs stopped due to these negative side effects.13,25-28

 

Participants in qualitative studies reflected on their experiences with vomiting and cramping.21,23,24,29,30 A participant in her forties disclosed, “I haven’t regretted using family planning, but I was constantly getting sick after doing the 3-month injectable method. So, I stopped and got pregnant with my last born because I knew it was the 3-month injectable that was making me sick.”31

 

Headaches

Headaches were cited as a significant factor for discontinuing hormonal contraceptive methods in 26% of the included studies. For example, in the study by Jaisamrarn et al., 26 33% of women discontinued oral hormonal contraceptives due to headaches. Headaches were a frequently experienced side effect in the qualitative literature as well.21,22,29 They were generally reported with complaints of fatigue and/or mood changes and emotional liability, but also remained a compelling single cause of dissatisfaction. One 19-year-old implant user who discontinued contraceptives explained, “I had migraines; I’d be sleeping all the time. The headaches were crazy. I could wake up in the night and my head would be banging”.21

 

Mood Changes

Several studies identified mood changes as one of the reasons for discontinuing hormonal contraception methods. Thirty-three percent of the studies in this review cited mood alterations as a reason for cessation, with rates of discontinuation varying between 1.7 and 50%.17,25 One 31-year-old participant described having a “short fuse at my husband and kids all the time, which isn’t healthy,” which led her to discontinue using hormonal contraception. 20 A 17-year-old implant user noted feelings of depression she experienced while using an implant: “That’s never happened before. I was actually quite frightened”.21

 

Sexual & Genitourinary Side Effects

Changes in sex drive and sexual pleasure were also recognized as contributing factors to hormonal contraceptive discontinuation. Studies reported that between 5.5% and 46.4% of women discontinuing LARCs did so at least in part due to reduced libido.25,28,32 Studies looking at hormonal contraceptives more broadly found that a change in sexual pleasure or painful intercourse contributed to the discontinuation of contraception in 2.7% to 7% of women, and that a change in sex drive played an even larger role, with 6.3 to 9.9% of women attributing their decision to forgo hormonal contraception methods to reduced libido.14,33

 

Sexually transmitted infections and genitourinary-specific side effects were considered in four studies. A small number of participants in these studies did experience GU symptoms, including vaginitis, pelvic pain, abnormal discharge, swelling of the labia minora, and pelvic inflammatory disease, which contributed to both IUD and implant discontinuation, as well as dissatisfaction with progestogen-only injectables.11,28,34-36

 

The effect of hormonal birth control on sexuality and sexual satisfaction repeatedly appeared in the qualitative literature.18,20,21,37  Women reported decreases in sex drive and the impact of abnormal and breakthrough bleeding on their sex lives.20,21,37 As one woman explained, “[I] didn’t have regular sex, normal sex because of periods, and I wouldn’t like to have sex with someone on their period, it’s just not nice, so that was pretty much problems, everyday problems.”22

Discussion

This review found that globally, more than one-quarter of women discontinue hormonal contraception within one year of initiation. Significantly, side effects heavily influence this choice, often outweighing the desire to continue the chosen hormonal contraceptive method—a finding that was consistent across diverse populations and varied geographic areas.

 

Abnormal bleeding and weight gain were the most frequently cited reasons for discontinuation, with each having ancilary factors that reinforced the decision to cease using hormonal contraception. For example, abnormal bleeding left women uncertain about their menstrual cycle, increased anemia among some patients, and interfered with women’s sex lives.

 

Early discontinuation has far-reaching implications on the health and welfare of women and the health system as a whole. The most immediate repercussion is the risk of unplanned pregnancies. Current threats on reproductive rights in the United States could make unplanned pregnancies increasingly hazardous due to restrictive abortion policies, which are linked to higher rates of increased maternal mortality.40 Further, this is ahealth equity issue, as Black women are less likely to receive an abortion referral when requested.41 The lack of abortion access, combined with racial disparities in maternal mortality, makes contraceptive continuation an important aspect of birth equity and a potentially life-saving practice.42 Moreover, at least ten countries in this review have stricter abortion restrictions than the United States, making contraception continuation an issue of global importance. 43

Strengths and Limitations

One notable strength of this review is the heterogeneity of the studies included, spanning various regions, types of hormonal contraceptive methods, and ranging over several years. However, given the statistical differences between contraception discontinuation between women from LMICs and women in the United States, future research should account for disparities that exist compared to high-income countries and diverse racial groups.

 

Another strength was the use of quantitative and qualitative methods, which provided added nuance in the synthesis process by capturing hard data on the number of people who discontinued hormonal contraception combined with people’s lived experiences concerning side effects and discontinuation. A clear limitation, however, was the absence of studies linking specific side effects to particular forms of hormonal contraception. This gap underscores the need for further research concerning the role side effects play and comprehensive pre-contraception counseling that addresses particular side effects for different methods.

Conclusion

Despite the growing popularity of hormonal contraceptives among women of reproductive age worldwide, the number of unintended pregnancies is still high. Our review indicates that many women appear to be discontinuing their chosen hormonal contraceptive method early due to contraceptive side effects. Future studies should explore stratageis for managing these side effects and explore additional ways to encourage consistent and continued use of contraception.


Acknowledgements

We want to thank Stella Seal, the Information Specialist who worked with us to finalize the search strategy and conduct the literature search in the database.

Disclosure Statement

The authors have no relevant financial disclosures or conflicts of interest.

References

  1. Bearak J, Popinchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health. Sep 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6
  2. Ali MM, Cleland JG, Shah IH, Organization WH. Causes and consequences of contraceptive discontinuation: evidence from 60 demographic and health surveys. 2012;
  3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. American journal of obstetrics and gynecology. Sep 1998;179(3 Pt 1):577-82. doi:10.1016/s0002-9378(98)70047-x
  4. Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? American journal of obstetrics and gynecology. 2007;196(4):412. e1-412. e7.
  5. Jain AK, Winfrey W. Contribution of Contraceptive Discontinuation to Unintended Births in 36 Developing Countries. Stud Fam Plann. Sep 2017;48(3):269-278. doi:10.1111/sifp.12023
  6. Campbell M, Sahin-Hodoglugil NN, Potts M. Barriers to fertility regulation: a review of the literature. Stud Fam Plann. Jun 2006;37(2):87-98. doi:10.1111/j.1728-4465.2006.00088.x
  7. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review. Journal of women’s health (2002). May 2015;24(5):349-53. doi:10.1089/jwh.2015.5191
  8. Staveteig S, Mallick L, Winter R. Uptake and discontinuation of long-acting reversible contraceptives (LARCs) in low-income countries. DHS analytical studies. 2015;(54)
  9. Branum AM, Jones J. Trends in long-acting reversible contraception use among US women aged 15-44. US Department of Health and Human Services, Centers for Disease Control and …; 2015.
  10. Stata Statistical Software: Release 16. Version Release 16. 2019. 2019. https://www.stata.com/
  11. Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria. Ann Afr Med. Jan-Mar 2012;11(1):27-31. doi:10.4103/1596-3519.91013
  12. Sundell M, Ginstman C, Mansson A, Forslund I, Brynhildsen J. Patterns of prescription and discontinuation of contraceptives for Swedish women with obesity and normal-weight women. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. Jun 2019;24(3):192-197. doi:10.1080/13625187.2019.1610873
  13. Madden T, Eisenberg DL, Zhao Q, Buckel C, Secura GM, Peipert JF. Continuation of the etonogestrel implant in women undergoing immediate postabortion placement. Obstet Gynecol. Nov 2012;120(5):1053-9. doi:10.1097/aog.0b013e3182632cd6
  14. Madden T, Secura GM, Nease RF, Politi MC, Peipert JF. The role of contraceptive attributes in women’s contraceptive decision making. American journal of obstetrics and gynecology. Jul 2015;213(1):46 e1-46 e6. doi:10.1016/j.ajog.2015.01.051
  15. Roberts AO, Morhason-Bello IO, Okunlola MA, Adekunle AO. Profile of Implanon® acceptors and pattern of side effects. J Reprod Contracept. 2015;26(1):46-52.
  16. Fruzzetti F, Paoletti AM, Fidecicchi T, Posar G, Giannini R, Gambacciani M. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access J Contracept. 2019;10:1-6. doi:10.2147/OAJC.S204655
  17. Fruzzetti F, Perini D, Fornaciari L, Russo M, Bucci F, Gadducci A. Discontinuation of modern hormonal contraceptives: an Italian survey. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. Dec 2016;21(6):449-454. doi:10.1080/13625187.2016.1234598
  18. Alspaugh A, Reibel MD, Im E-O, Barroso J. “Since I’ma little bit more mature”: contraception and the arc of time for women in midlife. Women’s Midlife Health. 2021;7(1):1-8.
  19. Dolan H, Li M, Bateson D, et al. ‘Every medicine is part poison’: a qualitative inquiry into the perceptions and experiences of choosing contraceptive methods of migrant Chinese women living in Australia. Bmc Womens Health. Mar 8 2021;21(1):1-13. doi:ARTN 100 10.1186/s12905-021-01226-3
  20. Flore M, Chen XS, Bonney A, et al. Patients’ perspectives about why they have their contraceptive Implanon NXT device removed early. Aust Fam Phys. Oct 2016;45(10):740-744.
  21. Hoggart L, Newton VL. Young women’s experiences of side-effects from contraceptive implants: a challenge to bodily control. Reprod Health Matters. May 2013;21(41):196-204. doi:10.1016/S0968-8080(13)41688-9
  22. Hoggart L, Newton VL, Dickson J. “I think it depends on the body, with mine it didn’t work”: explaining young women’s contraceptive implant removal. Contraception. 2013;88(5):636-640.
  23. Kelly MA, Bath EP, Godoy SM, Abrams LS, Barnert ES. Understanding Commercially Sexually Exploited Youths’ Facilitators and Barriers toward Contraceptive Use: I Didn’t Really Have a Choice. Journal of pediatric and adolescent gynecology. Jun 2019;32(3):316-324. doi:10.1016/j.jpag.2018.11.011
  24. Schmidt EO, James A, Curran KM, Peipert JF, Madden T. Adolescent Experiences With Intrauterine Devices: A Qualitative Study. J Adolesc Health. Oct 2015;57(4):381-6. doi:10.1016/j.jadohealth.2015.05.001
  25. Al-Jefout M, Nawaiseh N, Tashman S, et al. Jordanian Women’s Experience with Etonogestrel Subdermal Contraceptive Implant in Two Family Planning Clinics. Jordan Med J. 2015;49(1):27-35.
  26. Jaisamrarn U, Santipap M, Santibenchakul S. Discontinuation rates of different contraceptive methods in Thai women up to 1-year after method initiation. Sci Rep. May 24 2021;11(1):10819. doi:10.1038/s41598-021-90373-6
  27. Martin D, Sale C, Cooper SB, Elliott-Sale KJ. Period Prevalence and Perceived Side Effects of Hormonal Contraceptive Use and the Menstrual Cycle in Elite Athletes. Int J Sports Physiol Perform. Aug 1 2018;13(7):926-932. doi:10.1123/ijspp.2017-0330
  28. Saloranta TH, Gyllenberg FK, But A, Gissler M, Laine MK, Heikinheimo O. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons. American journal of obstetrics and gynecology. Dec 2020;223(6):886 e1-886 e17. doi:10.1016/j.ajog.2020.06.023
  29. Austad K, Shah P, Shryer H, Rohloff P, Chary A. A Qualitative Comparison of Long- and Short-acting Hormonal Method: Users’ Perspectives on Method Selection in Rural Guatemala. International Journal of Womens Health and Reproduction Sciences. Oct 2020;8(4):338-346. doi:10.15296/ijwhr.2020.55
  30. Berndt VK, Bell AV. Contextualizing barriers to long-acting reversible contraception in Delaware. Contraception. Jun 2021;103(6):439-443. doi:10.1016/j.contraception.2021.02.007
  31. Schrumpf LA, Stephens MJ, Nsarko NE, et al. Side effect concerns and their impact on women’s uptake of modern family planning methods in rural Ghana: a mixed methods study. Bmc Womens Health. Mar 20 2020;20(1):1-8. doi:ARTN 57 10.1186/s12905-020-0885-0
  32. Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. Feb 2014;19(1):5-14. doi:10.3109/13625187.2013.853034
  33. Simmons RG, Sanders JN, Geist C, Gawron L, Myers K, Turok DK. Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants. American journal of obstetrics and gynecology. Apr 2019;220(4):376. e1-376. e12. doi:ARTN 376.e1-e12 10.1016/j.ajog.2018.12.022
  34. Bachofner M, Blickenstorfer K, Hutmacher J, Wehrle L, Leeners B, Merki-Feld G. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. Dec 2018;23(6):407-414. doi:10.1080/13625187.2018.1539164
  35. Hladky KJ, Allsworth JE, Madden T, Secura GM, Peipert JF. Women’s Knowledge About Intrauterine Contraception. Obstetrics and Gynecology. Jan 2011;117(1):48-54. doi:10.1097/AOG.0b013e318202b4c9
  36. Wildemeersch D, Goldstuck ND, Jackers G. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. Mar 2017;33(3):223-226. doi:10.1080/09513590.2016.1276164
  37. Higgins JA, Ryder K, Skarda G, Koepsel E, Bennett EA. The Sexual Acceptability of Intrauterine Contraception: A Qualitative Study of Young Adult Women. Perspect Sex Reprod Health. Sep 2015;47(3):115-22. doi:10.1363/47e4515
  38. Dasari M, Borrero S, Akers AY, et al. Barriers to Long-Acting Reversible Contraceptive Uptake Among Homeless Young Women. Journal of pediatric and adolescent gynecology. Apr 2016;29(2):104-110. doi:10.1016/j.jpag.2015.07.003
  39. Cavallaro FL, Benova L, Owolabi OO, Ali M. A systematic review of the effectiveness of counselling strategies for modern contraceptive methods: what works and what doesn’t? BMJ sexual & reproductive health. 2020;46(4):254-269.
  40. Vilda D, Wallace ME, Daniel C, Evans MG, Stoecker C, Theall KP. State Abortion Policies and Maternal Death in the United States, 2015‒2018. American journal of public health. Sep 2021;111(9):1696-1704. doi:10.2105/AJPH.2021.306396
  41. Nobel K, Luke AA, Rice WS. Racial disparities in pregnancy options counseling and referral in the US South. Health Serv Res. Feb 2023;58(1):9-18. doi:10.1111/1475-6773.14049
  42. MacDorman MF, Thoma M, Declcerq E, Howell EA. Racial and Ethnic Disparities in Maternal Mortality in the United States Using Enhanced Vital Records, 2016‒2017. American journal of public health. Sep 2021;111(9):1673-1681. doi:10.2105/AJPH.2021.306375
  43. World Health Organiaztion. Global Abortion Policies Database: A tool to expand knowledge, encourage transparency, and promote accountability. . Accessed 2022 Nov 13. https://abortion-policies.srhr.org
  44.  

About the Author

Joni Roberts, DrPH, CHES

Dr. Roberts is an Assistant Professor in the Department of Kinesiology & Public Health at California Polytechnic State University. She is a public health researcher who specializes in women’s sexual and reproductive health, including maternal & child health, cultural beliefs, and implicit bias and health disparities.

Kathrine McNabb, MSN, RN

Katherine C. McNabb is a DNP/PhD candidate, a trainee with the Johns Hopkins Center for Infectious Disease and Nursing Innovation, and a National Institute of Allergy and Infectious Disease Fellow.  While her research typically focuses on HIV and related infectious diseases, in her nursing practice she is passionate about providing holistic care for people living with HIV, including comprehensive contraceptive care and sexual health services.

Alana J. Bergman, MSN AGNP-BC

Alanna J. Bergman is a PhD candidate at Johns Hopkins University School of Nursing and trainee in the Johns Hopkins Center for Infectious Disease and Nursing Innovation.  She is also a clinical nurse practitioner providing comprehensive care for people living with HIV.  Through that work, she provides gynecological care and advocates for reproductive equity for people of color, sexual and gender minorities and those marginalized by infectious disease status.  The National Institutes of Nursing Research funds her current research.

Tanjila Taskin, PhD, MPH

Dr.Taskin is a postdoctoral research associate in the Department of Biostatistics and Epidemiology at the University of North Texas Health Science Center. Her career goal is to prevent cancer by identifying early-life mechanisms, including sociocultural and environmental factors, as well as developing and testing novel, precisely targeted interventions that promote health behavior. Dr. Taskin’s current research work will be able to identify emerging adults who are at risk of developing HPV-associated morbidities and mortalities and will help to develop evidence-based interventions.

Bella Mualem, BS

Bella Mualem is a first year Masters of Public Health student at the University of Minnesota where she is concentrating in Maternal and Child Health under the Division of Epidemiology and Community Health. Her research and areas of interest are in sexual and reproductive health practices and increasing abortion access within the United States.

Oluwabunmi Ogungbe, PhD, MPH

Dr. Oluwabunmi “Bunmi” Ogungbe is an Assistant Professor at Johns Hopkins School of Nursing and Johns Hopkins Bloomberg School of Public Health. She is a cardiovascular epidemiologist dedicated to using her clinical, research, and public health expertise to improve cardiometabolic outcomes among populations experiencing social marginalization. She collaborates on several community-engaged multi-level interventions leveraging digital technologies to improve hypertension control and the management of chronic conditions. Dr. Ogungbe is an emerging leader in community-engaged research seeking to advance health equity, both locally in the US and globally.